Concurrent Cisplatin with radiotherapy improves outcomes in locally advanced squamous cell carcinomas of the head neck cancers. Cisplatin has been used in different doses in various schedules. The present study is designed to evaluate the compliance, clinical outcomes and long term side effects in two different dose schedules of cisplatin used as concurrent with radiotherapy. Total 50 patients were included in study from November 2015 to March 2017 with 25 patients in each group. Total radiotherapy dose planned was 70Gy/35# in 7weeks along with either cisplatin 35mg/m2weekly (Group I) or 6mg/m2 daily (Group II). Assessment of toxicity was done by RTOG  scoring criteria. WHO Response criterion was used to assess clinical response. The compliance for radiotherapy treatment (80% vs 84%) and chemotherapy cycles (52% vs 60%) were almost similar in both groups with no statistical difference seen. At the end of 3 months,Group II (60%) had better complete response than Group I (40%) though the difference was not statistically significant (p= 0.08). During treatment no Grade III/IV hemoglobin toxicity observed in either groups. Grade III/IV Mucositis which was predominant in Group II with 40% vs 24%, p value was not statistically significant. No Grade III/IV Xerostomia seen in either of the groups. The median follow up of patients is 15 months. The median OS (11 months vs 6 months) and DFS (4 months vs 2 months) are less in patients who received daily cisplatin infusion as concurrent therapy, though the difference is not statistically significant. Low dose cisplatin with radiotherapy appears feasible and logistically suitable "outpatient" option without increasing long term toxicity.

Ayush Garg, MD (Radiotherapy) from Shri Ram Murti Smarak Institute Of Medical Sciences, Bareilly, Certificate course in essentials of palliative care certified by Indian Association of Palliative Care, Clinical Fellow: Royal Marsden Hospital, NHS Trust Foundation, London. Area of interest: Head-neck cancers, Gynaecological malignancies, Breast cancer, Brain tumors and Palliative care. Honors & Awards: 1st prize in quiz competition RAD-ONC Conclave (National Meet) on Prostate Cancer, AROI overseas fellowship <35 years age category, Travel grant: Estro Meets Asia 2019, Singapore, 1st prize in quiz competition RAD-ONC Conclave (National Meet) on Prostate Cancer, Got the Chairman’s special appreciation and Best Faculty Award in Assistant Professor Category (Academic year 2021- 2022) for patient care, academic & research work and valued contribution towards development of the institute on the occasion of 20th Foundation Day at Shri Ram Murti Smarak Institute of Medical Sciences, Bareilly, Awarded with Young Change Maker Award 40 under 40 categories in The Young Change Maker Summit and Awards 2022. Number of publications: International- 3, National- 10.